The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C

  • Ekkaphon Metharom
  • , Peter Galettis
  • , Susan Manners
  • , Maria Jelinek
  • , Winston Liauw
  • , Paul L De Souza
  • , Janelle M Hoskins
  • , M. Links*
  • *Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Fingerprint

Dive into the research topics of 'The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases